Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
yrdC N(6)-threonylcarbamoyltransferase domain containing pseudogene 2 (YRDCP2) is a human pseudogene located in the genome, indicated by its standardized symbol YRDCP2[5][7]. As a pseudogene, it does not produce a functional protein and is not known to play a direct biological role or to be classified among traditional drug target families such as receptor, enzyme, transporter, or transcription factor[5][7]. There is no evidence in current research that YRDCP2 acts as a therapeutic target or that it is involved in any disease pathology, biomarker profiling, or drug interactions. Its classification as a “pseudogene” distinguishes it from other protein-coding or functional RNA genes, and there are no reported aliases or disease associations, mechanisms of action, safety concerns, or use as a therapeutic biomarker[5][7]. The functionally related gene, YRDC, encodes a protein involved in tRNA modification, but YRDCP2 itself is inactive and considered biologically inert[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on yrdC N(6)-threonylcarbamoyltransferase domain containing pseudogene 2 (YRDCP2).